WS19.03 Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) – interim analysis using automated LungQ scoring
P. McNally, H. Tiddens, J.C. Davies(Royal Brompton Hospital), B. Elnazir, Stuart McGrane(Vanderbilt University), D. Caudri(Erasmus University Rotterdam), B. Linnane, D. Cox, M Bönte(Erasmus University Rotterdam), Thomas Semple, P. O’Regan(University College Cork), David Rea(Children's Health Ireland at Crumlin), P. Makani(Erasmus University Rotterdam), T. V. N. Persaud(Children's Health Ireland at Crumlin), M. Williamson(Children's Health Ireland at Crumlin), E. Twomey(Children's Health Ireland at Crumlin), K. Lester(Children's Health Ireland at Crumlin), L. Kirwan(Cystic Fibrosis Ireland), Rachel Cregan
Cited by 0
Related Papers
Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial
|Critical Care|2010|417
Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group
|Familial Cancer|2021|53
Short-Term sequelae of Multisystem Inflammatory Syndrome in Children Assessed by CMR
|JACC. Cardiovascular imaging|2021|22
A comprehensive regional neurochemical theory in depression: a protocol for the systematic review and meta-analysis of 1H-MRS studies in major depressive disorder
|Systematic Reviews|2018|15
Computed tomography in constrictive pericarditis.
|PubMed|1984|3